glp-1 compounding news november 2025 fda semaglutide enforcement The FDA has released new guidance for providers prescribing FDA Warns 25 Firms Over

I love this journal because it encourages consistency and helps you recognize non-scale victoriesnot just the number on the scale

Thyroid hormone biomonitoring: A review on their metabolism and machine-learning based analysis on effects of endocrine disrupting chemicals

Individuals seeking brighter and radiant skin

Three children with available imaging at the time of diagnosis were included in the study

Euglycemic diabetic ketoacidosis is another concern that may delay initiation or result in early discontinuation of SGLT2i therapy [4, 19]

Compliance and Legal Considerations for Compounders The pharmacy compounding industry faces increased scrutiny due to: More vigorous FDA enforcement against unapproved compounded medications